Lotus Technology Inc. shares rise 1.91% after-hours following positive EMA recommendation for Alvotech's biosimilar.

Lotus Technology Inc. rose 1.91% in after-hours trading, following the news that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending approval for Gobivaz, Alvotech's proposed biosimilar to Simponi (golimumab). This development is expected to increase access for patients and healthcare professionals to golimumab, which is an important treatment option for several chronic inflammatory diseases.